NASDAQ:VSTM - Verastem Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$3.30 +0.22 (+7.14 %)
(As of 02/15/2019 04:00 PM ET)
Previous Close$3.30
Today's Range$3.08 - $3.39
52-Week Range$2.77 - $10.35
Volume2.70 million shs
Average Volume2.21 million shs
Market Capitalization$243.51 million
P/E Ratio-1.88
Dividend YieldN/A
Verastem, Inc., operating as Verastem Oncology, is a biopharmaceutical company focusing on developing and commercializing medicines to improve the survival and quality of life of cancer patients. It markets COPIKTRA (duvelisib), an oral inhibitor of phosphoinositide 3-kinase (PI3K) and dual inhibitor of PI3K-delta and PI3K-gamma, which is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma after at least two prior therapies and relapsed or refractory follicular lymphoma (FL) after at least two prior systemic therapies. The indication in FL is approved under accelerated approval based on overall response rate. The company is also developing a dual inhibitor of PI3K-delta and PI3K-gamma, which has completed Phase 2 study in indolent non-hodgkin lymphoma. In addition, it is developing the focal adhesion kinase inhibitor defactinib, which is being evaluated in three separate clinical collaborations in combination with immunotherapeutic agents for the treatment of various different cancer types, including pancreatic cancer, ovarian cancer, non-small cell lung cancer (NSCLC), and mesothelioma. Verastem, Inc. has collaboration agreements with Yakult Honsha Co., Ltd. and The Leukemia & Lymphoma Society. The company was founded in 2010 and is headquartered in Needham, Massachusetts.

Receive VSTM News and Ratings via Email

Sign-up to receive the latest news and ratings for VSTM and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:VSTM



Sales & Book Value

Annual SalesN/A
Book Value$1.19 per share


Net Income$-67,800,000.00


Market Cap$243.51 million

Verastem (NASDAQ:VSTM) Frequently Asked Questions

What is Verastem's stock symbol?

Verastem trades on the NASDAQ under the ticker symbol "VSTM."

How were Verastem's earnings last quarter?

Verastem Inc (NASDAQ:VSTM) released its quarterly earnings data on Thursday, November, 8th. The biopharmaceutical company reported ($0.29) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.43) by $0.14. The biopharmaceutical company had revenue of $15.51 million for the quarter. View Verastem's Earnings History.

When is Verastem's next earnings date?

Verastem is scheduled to release their next quarterly earnings announcement on Tuesday, March 12th 2019. View Earnings Estimates for Verastem.

What price target have analysts set for VSTM?

6 analysts have issued 12-month target prices for Verastem's stock. Their predictions range from $12.00 to $17.00. On average, they expect Verastem's stock price to reach $15.4286 in the next twelve months. This suggests a possible upside of 367.5% from the stock's current price. View Analyst Price Targets for Verastem.

What is the consensus analysts' recommendation for Verastem?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Verastem in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Verastem.

What are Wall Street analysts saying about Verastem stock?

Here are some recent quotes from research analysts about Verastem stock:
  • 1. According to Zacks Investment Research, "Verastem, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing drugs to improve outcomes for patients with cancer. Its programs target the focal adhesion kinase (FAK) and the phosphoinositide 3-kinase (PI3K)/mTOR signaling pathways. Its lead FAK inhibitor is defactinib (VS-6063), an orally available candidate for combination therapy with immuno-oncology agents and other anti-cancer compounds. The company's defactinib is in Phase 1b study for the treatment of pancreatic cancer, as well as in Phase 1/2 clinical trial for the treatment of ovarian cancer, non-small cell lung cancer, mesothelioma, and pancreatic cancer. It also engages in developing duvelisib, an investigational oral therapy that targets the PI3K signaling pathway, as well as attacks malignant B-cells and T-cells and disrupt the tumor microenvironment to help thwart their growth and proliferation for patients with lymphatic cancers through the dual inhibition of PI3K delta and gamma. " (2/15/2019)
  • 2. HC Wainwright analysts commented, "Olga Smolentseva, Ph.D. – (646-975-6966) / [email protected] Our Takeaways From Verastem Investor Day; Reiterate Buy We anticipate duvelisib approval in 4Q18. On May 2, Verastem Oncology held an Analyst and Investor Day in New York and provided an overview on duvelisib’s development and management’s plans for the drug’s commercial launch. Recall, on February 7, Verastem filed a NDA application for duvelisib, the company’s dual PI3K-γ/δ inhibitor, for the treatment of relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma (r/r CLL/ SLL). The company has also filed for an accelerated approval of duvelisib for the treatment of follicular lymphoma (FL). We note that the FDA has granted a priority review for the duvelisib application, with the PDUFA date scheduled for October 5." (5/3/2018)
  • 3. Cantor Fitzgerald analysts commented, "Working off Overhangs. We think VSTM shares are undervalued relative to the duvelisib opportunity, and this is partly a function, in our view, of overhangs, particularly cash. VSTM had just under $87 mln in cash, which is sufficient to fund the company into 2H18, but will need additional capital to see duvelisib through commercialization. VSTM has an additional $35 mln available under a debt facility, and the company could add additional cash through a partner deal. It has been our anticipation that VSTM will need to address the capital markets in some way in 2018." (3/13/2018)

Has Verastem been receiving favorable news coverage?

Media stories about VSTM stock have been trending neutral this week, according to InfoTrie. The research group identifies positive and negative media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Verastem earned a media sentiment score of 0.2 on InfoTrie's scale. They also gave press coverage about the biopharmaceutical company a news buzz of 3.0 out of 10, indicating that recent media coverage is unlikely to have an effect on the company's share price in the near term.

Are investors shorting Verastem?

Verastem saw a increase in short interest in January. As of January 31st, there was short interest totalling 22,117,124 shares, an increase of 7.8% from the January 15th total of 20,515,566 shares. Based on an average daily trading volume, of 2,391,652 shares, the days-to-cover ratio is currently 9.2 days. Approximately 30.7% of the shares of the stock are short sold. View Verastem's Current Options Chain.

Who are some of Verastem's key competitors?

Who are Verastem's key executives?

Verastem's management team includes the folowing people:
  • Mr. Robert Forrester, Pres, CEO & Director (Age 55)
  • Mr. Richard H. Aldrich Mba, Founder and Consultant (Age 65)
  • Dr. Robert A. Weinberg, Co-Founder and Chair of Scientific Advisory Board
  • Dr. Piyush B. Gupta, Co-Founder
  • Dr. Michelle Dipp, Co-Founder (Age 43)

Who are Verastem's major shareholders?

Verastem's stock is owned by a variety of of institutional and retail investors. Top institutional investors include BlackRock Inc. (7.62%), Millennium Management LLC (1.69%), Two Sigma Investments LP (1.67%), Dimensional Fund Advisors LP (1.47%), Citigroup Inc. (1.23%) and Northern Trust Corp (1.12%). Company insiders that own Verastem stock include Dan Paterson, Joseph M Lobacki, Michael Kauffman, Robert Forrester, Steven H Bloom and Timothy J Barberich. View Institutional Ownership Trends for Verastem.

Which major investors are selling Verastem stock?

VSTM stock was sold by a variety of institutional investors in the last quarter, including Barclays PLC, Northern Trust Corp, MetLife Investment Advisors LLC, Bank of New York Mellon Corp, Stifel Financial Corp, Algert Global LLC, Raymond James & Associates and Howland Capital Management LLC. View Insider Buying and Selling for Verastem.

Which major investors are buying Verastem stock?

VSTM stock was bought by a variety of institutional investors in the last quarter, including Millennium Management LLC, Two Sigma Investments LP, BlackRock Inc., Citigroup Inc., Dimensional Fund Advisors LP, Two Sigma Advisers LP, RBF Capital LLC and B. Riley Financial Inc.. Company insiders that have bought Verastem stock in the last two years include Dan Paterson, Joseph M Lobacki, Michael Kauffman, Robert Forrester, Steven H Bloom and Timothy J Barberich. View Insider Buying and Selling for Verastem.

How do I buy shares of Verastem?

Shares of VSTM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Verastem's stock price today?

One share of VSTM stock can currently be purchased for approximately $3.30.

How big of a company is Verastem?

Verastem has a market capitalization of $243.51 million. The biopharmaceutical company earns $-67,800,000.00 in net income (profit) each year or ($1.76) on an earnings per share basis. Verastem employs 69 workers across the globe.

What is Verastem's official website?

The official website for Verastem is

How can I contact Verastem?

Verastem's mailing address is 117 KENDRICK STREET SUITE 500, NEEDHAM MA, 02494. The biopharmaceutical company can be reached via phone at 781-292-4200 or via email at [email protected]

MarketBeat Community Rating for Verastem (NASDAQ VSTM)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  396 (Vote Outperform)
Underperform Votes:  268 (Vote Underperform)
Total Votes:  664
MarketBeat's community ratings are surveys of what our community members think about Verastem and other stocks. Vote "Outperform" if you believe VSTM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VSTM will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/16/2019 by Staff

Featured Article: Straddles

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel